6

## Remarks

Claims 1 to 8 are pending in the application in their original format.

Claims 9 to 26 are hereby withdrawn.

Applicant reserves the right to request a rejoinder of the withdrawn subject matter as well as filing subsequent divisional applications.

In response to the Office Action on May 2, 2008, applicant elects invention of group 1 directed to "a method for modulating at least one immune cell type in a patient suffering from neutropenia" as claimed in claims 1 to 8.

Furthermore, Applicant hereby submits a declaration from Dr. Philippe A. Tessier stating that the publication from Ryckman *et al.* (Journal of immunology, 2003, March 15, Vol. 170 (6). 3233 to 3242) emanates from the same inventive entity as the co-inventors on the instant patent application. The Examiner is therefore requested to withdraw this citation against the invention of group 1 (claims 1 to 8).

No new matter has been added by way of the present amendments.

It is submitted, therefore, that the claims are in condition for allowance. Reconsideration of the examiner's rejections is respectfully requested and allowance of claims 1 to 8 at an early date is earnestly solicited.

In the event that there are any questions concerning this amendment or the application in general, the Examiner is respectfully urged to telephone the undersigned so that prosecution of this application may be expedited.

No fees are believed to be required by the present response. However, should this be an error, authorization is hereby given to charge deposit account 19-5113 for any underpayment or to credit any overpayment.

Respectfully submitted,

Louise G. Bernier, Ph.D

Reg. No. 38,791 Agent for the Applicant OGILVY RENAULT, LLP Customer number: 020988

encl. Declaration of P. Tessier and c.v.